Core Laboratories Joint Venture Agreement
VIBGYOR Scientific Research, genae associates, Cardiovascular Center Aalst and J.B. Dahm, MD have reached an agreement to form a Core Laboratories joint venture, called imaeon.
Core Laboratories joint venture agreement between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
6 October 2008 - Antwerp, Ahmedabad, Aalst, Göttingen
VIBGYOR Scientific Research, genae associates, Cardiovascular Center Aalst and J.B. Dahm, MD have reached an agreement to form a Core Laboratories joint venture, called imaeon.
imaeon initially will focus on the performance of medical images analysis for clinical research projects, including but not limited to: quantitative coronary and peripheral angiography (QCA, QVA), computed tomography (CT) angiography, intravascular ultrasound (IVUS) and IVUS related
techniques, multiple gated acquisition scan (MUGA), optical coherence tomography (OCT), magnetic resonance imaging (MRI), multi slice computer tomography (MSCT), electrocardiogram (ECG) and ECHO assessments.
While meeting or exceeding all quality standards in a timely and cost-effective manner, imaeon will offer expert evaluations of medical images from multi-modality environments and unsurpassed quality clinical research services. It will operate from the main facilities and offices in Ahmedabad,
India and from the subsidiary in Antwerp, Belgium and focus on the pharmaceutical, biomedical and medical device industries.
About Cardiovasculair Onderzoek Aalst CVBA
Cardiovasculair Onderzoek Aalst, with principal offices in Aalst, Belgium, provides consultancy assignments and logistics support related to scientific research and scientific studies for physicians, hospitals, universities, pharmaceutical institutions, governments and governmental institutions.
Contact
Paul Nellens, MD - paul.nellens@olvz-aalst.be
About genae associates nv
genae is a privately held NV/SA with principal offices in Antwerp, Belgium and is ISO 9001:2000 certified for CRO, Core Laboratories and Services Provider for the Medical Industries. These global services include but are not limited to Clinical Data Management, Electronic Data Capture
(EDC), Statistical Analysis, Scientific & Medical Writing, CE-Marking (MDD) and Training & Education.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
